BACKGROUND: Extracellular matrix alterations are important elements in the arterial changes seen in diabetes, being associated with increased vascular stiffness and the development of cardiovascular diseases. However, no biomarkers for diabetes-related arterial changes have been defined.
The arterial pathology in diabetes not only includes an increased atherosclerotic plaque burden but also generalized arterial alterations. These alterations comprise endothelial dysfunction, extracellular matrix (ECM) changes, and increased stiffness, present also in nonatherosclerotic parts of the arterial tree. Increased stiffness can be detected in diabetes in nonatherosclerotic arterial tissue, both when evaluated in vivo (3 ) , and in excised arterial tissue (4 ) . The biomechanical alterations are associated with generalized changes in the vascular ECM, where accumulation of glycosaminoglycans (5 ) and glycoproteins (6, 7 ) , including collagens (8 ) , occurs together with an increased degree of collagen glycation-derived crosslinking (4, 8 -10 ) . ECM turnover is also altered in diabetic arterial tissue as evidenced by increased concentrations of the metalloproteinase matrix metallopeptidase 2 (MMP-2) (11, 12 ) , a proteinase that cleaves elastin associated with vascular stiffness (13 ) . Some studies have revealed signs of elastolysis and altered elastin content in diabetic arteries (14 -16 ) . Otherwise, no information is available about elastin and elastin-associated matrix molecules, such as fibulins, in relation to diabetic arteriopathy.
We hypothesized that dysregulated genes related to arterial alterations in diabetes could be identified by global RNA-array screening of nonatherosclerotic arterial tissue from patients with T2DM. Our investigations led to the identification of a candidate molecule, fibulin-1, an elastin-associated matrix molecule, which is also present in large concentrations in plasma.
Materials and Methods

POPULATION 1 AND 2: GENE DISCOVERY AND VALIDATION
STUDIES IN ARTERIAL TISSUE
All participants in all populations gave written informed consent, and all aspects of the study were approved by the local ethics committees. Participants for arterial tissue studies were recruited from patients undergoing artery bypass graft surgery at Skejby and Odense University Hospital. Participants for RNA analysis and histology included 10 men with more than 2 years known duration of T2DM, defined as diabetes, as registered in the patient file and diagnosed after adolescence, and 11 nondiabetic men matched according to age (population 1, Table 1 ). The waste part of the repair artery, i.e., the internal mammary artery,was obtained from each study participant. A small piece of the artery was removed for histological analysis, and the rest was dissected into intima/media-containing preparations and used for RNA isolation. Similarly, intima/media preparations from 2 groups (diabetic, n ϭ 7; nondiabetic, n ϭ 7) were gathered for protein extraction and fibulin-1 quantification (population 2, Table 1 ).
POPULATION 3: PLASMA FIBULIN-1 CASE-CONTROL STUDY (T2DM VS NONDIABETES)
EDTA-anticoagulated blood was obtained from 34 patients with T2DM (defined as above) and 36 sex-and age-matched persons without diabetes, randomly selected from individuals undergoing vascular surgery (coronary bypass or carotid atherectomies) at Skejby and Odense University Hospital, Denmark (population 3, Table 1 ). Plasma was stored at Ϫ80°C. EDTA-anticoagulated blood for analysis of plasma fibulin-1 was obtained from 305 T2DM patients without known or suspected CVD, consecutively referred to the outpatient diabetes clinic at Odense University Hospital, Denmark (17 ) (population 4, Table 1 ). The definition of T2DM of the included patients included fasting C-peptide Ͼ250 pmol/L. Of these patients 45 were treated with acetyl salicylic acid, 192 with a statin, 62 with a calcium antagonist, 118 with a diuretica, 113 with an angiotensin-converting enzyme inhibitor, 70 with an angiotensin 2 receptor inhibitor, 188 with metformin, 75 with sulfonylurea, and 72 with insulin. Plasma was stored at Ϫ80°C. This study was based on a prospective follow-up study of all T2DM patients Ͻ66 years old who were treated at Hvidöre Hospital in 1987 (population 5, Table 1 ). EDTA-plasma specimens from baseline investigation, available from 308 of 315 patients followed for 15 years (range 0 -17 years) (18 ) were analyzed for fibulin-1. All patients were traced through the Danish National Register. If a patient had died, information on the cause of death was obtained from the death certificate. All death certificates were reviewed independently by 2 observers and the primary cause of death recorded. Additional available information from necropsy reports was included. All deaths were classified as cardiovascular deaths unless an unequivocal noncardiovascular cause was established (19 ) . Plasma was stored at Ϫ80°C.
RNA ISOLATION AND MICROARRAY HYBRIDIZATION
Total RNA was isolated from intima-media samples by use of the TRIzol protocol (Life Technologies). Quantity and quality of purified RNA were assessed with the NanoDrop spectrophotometer ND-8000 (NanoDrop Technologies) and Agilent 2100 Bioanalyzer (Agilent Technologies), respectively. Purified RNA was converted to biotin-labeled amplified RNA (aRNA) and fragmented by the MessageAmp TM II-Biotin singleround aRNA amplification kit (Ambion). Fragmented aRNA from individual samples was hybridized to Affymetrix HG-U133A 2.0 chips (Affymetrix). Glyceraldehyde-3-phosphate dehydrogenase and ␤-actin (HSACO7) 3Ј-to-5Ј probeset hybridization ratios were below 2.13 for all chips and confirmed the presence of high-quality RNA.
MICROARRAY DATA PROCESSING
The affy package (www.bioconductor.org/packages/ release/bioc/html/affy.html) was employed for initial data analysis. All intensity values were background corrected and normalized by use of the variancestabilizing normalization method (20 ) , and gene expression index computation was done by using model-based index calculation (21 ) . Only perfect match probes were used for data analysis. The regularized t-test limma (www.bioconductor.org/packages/ release/bioc/html/limma.html) was applied to evaluate differences in gene expression between individual samples from patients with diabetes and controls. Genes with an uncorrected P Ͻ 0.05 were considered for further analysis. Micorarray data generated by this project are available from GEO (Gene Expression Omnibus) (http://www.ncbi.nlm.nih.gov/geo, accession no. GSE13760).
QUANTITATIVE REAL-TIME PCR
We performed quantitative real-time PCR (q-RT-PCR) using random hexamer primers and Taqman gene expression assays (Applied Biosystems Prism 7700) for von Willebrand factor (VWF) 12 (Hs01109460_m1); leptin (LEP) (Hs00174877_m1); matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (MMP2) (Hs00234422_m1); fibulin 1 (FBLN1) (Hs00242546_ m1); and fibulin 2 (FBLN2) (Hs01002054_m1). Expression changes for each gene were normalized to the expression level of the housekeeping gene actin, beta (ACTB) (Applied Biosystems).
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Tissue for histology was fixed in PBS (10 mmol/L phosphate, 150 mmol/L NaCl, pH 7.2)-buffered 4% formaldehyde and subsequently embedded in paraffin. Sections were cut and stained either by hematoxylin-eosin, von Kossa, or elastin (Verhoeff's) or subjected to antigen retrieval by incubating at 60°C overnight in a 10 mmol/L citrate buffer solution (Dako) in Tris-buffered saline (pH 6.0). Slides were stained with fibulin-1 anti- Systolic blood pressure, mmHg 154 (17) 143 (36) 131 (16) 131 (16) 147 (21) 144 (30) 139 (18) 150 (23) Diastolic blood pressure, mmHg 88 (9) 76 (12) g 80 (9) 80 (9) 83 (10) 78 (14) 79 (11) 85 ( bodies and evaluated quantitatively as described in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol57/ issue11.
ARTERIAL PROTEIN EXTRACTION AND QUANTIFICATION
Frozen intima-media-containing arterial tissue specimens (10 -15 mg) were placed in a CelLytic buffer (Sigma-Aldrich) containing 0.01% protease inhibitor cocktail at a ratio of 10 mg tissue to 200 L buffer. The tissue samples were homogenized by a Qiagen Tissue Lyser using a 5-mm stainless steel bead for 2 min by 25 Hz at 0°C. The solution was cleared by 10 min centrifugation at 20 000g, 4°C. Protein was quantified in the extracts by Bradford assay.
BIOCHEMICAL ANALYSIS
A sandwich immunoassay for fibulin-1 was set up that was based on a previously described method (22 ) , as described in detail in the online Supplementa Data file. Plasma total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatinine, and glucose were analyzed on a Modular Analytics P (Roche Diagnostics). High-sensitivity C-reactive protein concentrations were determined with a particle immunoassay rate method (IMMAGE; Beckman Coulter). Hemoglobin A 1c (Hb A 1c ) was measured by cation exchange chromatography using Tosoh G7 (Medinor). Urine albumin/creatinine ratios were analyzed by Modular Analytics P (Roche Diagnostics).
ECHOCARDIOGRAPHY, CAROTID INTIMA-MEDIA THICKNESS, AND COMPLIANCE MEASUREMENTS
Echocardiograms were obtained and stored digitally for subsequent blinded analysis as described previously (23 ) and as summarized in the online Supplemental Data file. Similarly, B-mode ultrasound of the carotid artery was performed (24 ) as described in the online Supplemental Data file.
STATISTICAL METHODS
Continuous variables are presented as mean (SD) or (SE), and categorical variables as numbers and as percentages with 95% CIs. A Student t-test was used to judge differences between independent continuous variables. Univariate analysis results are presented as Pearsons correlations, whereas we analyzed multivariate correlations by simple partial correlation analysis for continuous variables, using SPSS 17.0. We used multiple linear regression, with backward selection, to judge parameters of significance for the prediction of blood pressure in population 4. Cox proportional hazard models were used to evaluate fibulin-1 as a predictor of overall or cardiovascular mortality. The adjusted hazard ratio was calculated after adjustment for age, sex, Hb A 1c , previous myocardial infarction (MI), systolic blood pressure, total cholesterol, and smoking.
Results
PATIENT CHARACTERISTICS
Information about all 5 populations, including age, sex, systolic and diastolic blood pressure, and biochemical data, can be found in Table 1 . As expected, T2DM patients showed a significantly higher Hb A 1c . Diastolic blood pressure was significantly higher in the control group of population 1 than the diabetic group in this population ( Table 1 ). The concentrations of total cholesterol and HDL cholesterol were slightly lower in individuals with diabetes in population 3.
IDENTIFICATION OF FIBULIN-1 BY GLOBAL GENE EXPRESSION ANALYSIS IN NORMAL-APPEARING TISSUE IN DIABETES
All arterial samples appeared normal by histological examination, i.e., without atherosclerosis, calcified areas, or cellular infiltrations, as revealed by von Kossa, hematoxylin-eosin, and elastin staining. Analysis of the individual arterial DNA microarray data in population 1 revealed 477 genes downregulated and 169 upregulated in T2DM patients compared with arterial RNA from controls (P Ͻ 0.05, t-test without correction for multiple testing, population 1). No gene was significantly differentially expressed after we controlled for multiple hypothesis testing using the BenjaminiHochberg method. Among genes with a noncorrected P value Ͻ0.05, the top 11 genes are presented in Table  2 and sorted according to fold change. Among the upregulated genes, FBLN1 displayed the highest level of fold change. q-RT-PCR analysis of 5 of the 11 most upregulated genes (FBLN1, VWF, FBLN2, MMP2, and LEP) showed that 3 genes, FBLN1, VWF, and FBLN2, were significantly upregulated ( Table 2) .
FIBULIN-1 IN THE ARTERIAL EXTRACELLULAR MATRIX
Immunohistological analysis showed fibulin-1 immunolabeling to be present throughout the layers of the arterial wall (Fig. 1A) . A moderate degree of staining was apparent just beneath the endothelium in association with the internal elastic membrane. Weak to moderate staining was apparent in the middle part of the tunica media around vascular smooth muscle cells and intense immunostaining was seen in the outermost part of tunica media in association with the external elastic lamina at the border of the tunica adventitia. Unbiased, quantitative assessment of the area fraction of fibulin-1 immunostained material in each of the above locations revealed that the staining intensity was increased in diabetes in the border between media and adventitia, adjacent to external elastic membranes (P ϭ 0.04) (Fig. 1E) . Measurement of the concentrations of fibulin-1 in extracts of intima-media-containing artery samples showed a trend toward increased amounts in tissue from 7 T2DM patients compared with 7 nondiabetic controls (population 2) (P ϭ 0.06) (Fig. 2A) .
PLASMA CONCENTRATIONS OF FIBULIN-1 ARE INCREASED IN T2DM AND CORRELATE TO GLYCEMIC STATUS
The concentration of fibulin-1 in plasma was found to be significantly higher (P ϭ 0.006) in the diabetic group [74.9 (4.5) g/mL] than in the nondiabetic group [60.4 (2.5) g/mL] (population 3) (Fig. 2) . Plasma fibulin-1 concentrations were also measured in 305 T2DM patients without known CVD (population 4), for whom we observed a positive correlation to age (r ϭ 0.203, P Ͻ 0.001). Moreover, age-adjusted, significant correlations to Hb A 1c , fasting plasma glucose, and plasma creatinine were observed (Table 3) . Patients in population 4 with urinary albumin/creatinine ratios Ͼ3.5 mg/mmol were found to have significantly higher (P ϭ 0.01) plasma fibulin-1 concentrations [81.0 (2.3) g/mL, n ϭ 88] than patients whose values for albumin/creatinine ratios were Ͻ3.5 mg/mmol [75.6 (1.3) g/mL, n ϭ 202]. No correlations were observed between plasma fibulin-1 concentrations and either fasting plasma-insulin concentrations, lipid concentrations, body mass index (BMI), or highsensitivity C-reactive protein (hsCRP). There were no sex differences in plasma concentrations in the diabetic or the nondiabetic groups. Patients in population 4 treated with metformin had lower plasma fibulin-1 concentrations than patients not treated [76 (1.4) g/mL vs 81.4 (2.0) g/mL; P ϭ 0.03]. However, the correlation between fibulin-1 and Hb A 1c , systolic blood pressure, and NT-proBNP were present in patients with and those without metformin. There was no apparent influence of other antidiabetic treatments on fibulin-1 concentrations.
PLASMA FIBULIN-1 CONCENTRATIONS CORRELATE WITH CARDIOVASCULAR VARIABLES
Among the 305 T2DM patients without known CVD (population 4), age-adjusted correlations were found between plasma fibulin-1 concentrations and several indices related to vascular function, i.e., pressure and stiffness, systolic and diastolic blood pressure, pulse pressure, stroke-volume index/pulse pressure ratio (SVi/PP) (determined by echocardiography), and carotid compliance (determined by carotid ultrasonography) (Table 3) . A statistically significant positive correlation was also observed between plasma fibulin-1 concentrations and measures of cardiac function, i.e., left atrial volume index and plasma NT-proBNP (Table  3 ). The intake of statins, diuretics, acetyl salicylic acid, calcium antagonists, angiotensin-converting enzyme inhibitors, and angiotensin 2 receptor inhibitors showed no apparent effect on fibulin-1 concentrations. Among the 20 patients in population 4 who did not receive any medication, the unadjusted correlation coefficient between plasma fibulin-1 and Hb A 1c was 0.44 (P ϭ 0.05), whereas it was 0.37 (P ϭ 0.11) for the correlation between fibulin-1 and systolic blood pressure.
The correlations between plasma fibulin-1 and all cardiovascular parameters as well as Hb A 1c were significant in patients in whom U-albumin/creatine was below and those in whom it was above 3.5 mg/mmol. Using backward selection in a multiple regression analysis, we found that only fibulin-1 (␤ ϭ 0.346; P Ͻ 0.001) and BMI (␤ ϭ 0.144, P ϭ 0.008) were predictive for systolic blood pressure, whereas age, sex, NTproBNP, Hb A 1c , hsCRP, LDL, HDL, and triglycerides were excluded from the model.
PLASMA FIBULIN-1 CONCENTRATIONS PREDICT MORTALITY
During a median of 15 years of follow-up, a total of 157 patients (51%) in population 5 died, of whom 115 (37%) died of cardiovascular causes. Mean (SD) plasma fibulin-1 concentrations were 49 (16) g/mL.
Increased plasma fibulin-1 concentrations were associated with higher overall mortality and cardiovascular mortality (Fig. 3) . In a Cox regression model for allcause mortality the hazard ratio (HR) (95% CI) for a change in fibulin-1 of 1 SD (16 g/mL) was 1.29 (1.11-1.49) (P ϭ 0.001). After adjustment for age, sex, cholesterol, previous MI, Hb A 1c , systolic blood pressure, and smoking status, the HR was 1.24 (95% CI 1.05-1.47) (P ϭ 0.013). By comparison, the HR for a change in systolic blood pressure of 1 SD (23 mmHg) was 1.27 (1.08 -1.49) and 1.21 (1.04 -1.42) for a change in total cholesterol of 1 SD (1.7 mmol/l). For cardiovascular mortality, the unadjusted HR for a change in fibulin-1 Circumferential sections of a mammary artery stained with fibulin-1 antibodies (A) and without primary antibody (B). The area fraction of fibulin-1-stained material was determined quantitatively in nondiabetic and diabetic arterial tissues within (C) the tunica intima, (D) the tunica media, and (E) the border between the tunica media and the tunica adventitia, associated with external elastic membranes as indicated. Patients are from population 1 (T2DM, n ϭ 7; control, n ϭ 7), and values are presented as mean (SE) (*P ϭ 0.04). Ext. elast. mem., external elastic membrane.
Fibulin-1 in Diabetes of 1 SD was 1.26 (1.06 -1.50) (P ϭ 0.01) and after adjustment 1.18 (0.97-1.44) (P ϭ 0.098).
Discussion
In the present study, we observed that the expression of mRNA encoding fibulin-1 was increased in normalappearing, nonatherosclerotic arterial tissue from patients with T2DM. Fibulin-1 is an ECM protein (25, 26 ) that is found in elastic fibers and basement membranes in blood vessels and other elastincontaining tissues (27 ) . It is predominantly expressed in the great vessels during embryogenesis. Fibulin-1 binds other ECM molecules such as elastin, fibronec- Overall mortality (A) and cardiovascular mortality (B) in 308 T2DM patients (population 5) grouped in tertiles according to plasma fibulin-1 concentrations (blue is the group with the lowest, green the group with intermediate, and black with the highest concentrations of plasma fibulin-1). In A, log rank P ϭ 0.003. In B, log rank P ϭ 0.047.
tin, and proteoglycans, but its function in the vasculature is uncertain. Fibulin-1 deficiency in mice causes blood vessel abnormalities, particularly dilations and rupture, leading to massive hemorrhages and perinatal death (28, 29 ) . Little is known about the role of fibulin-1 in CVDs other than the fact that it is present in atherosclerotic lesions (30 ) and that its transcript is downregulated in aortic tissue from patients with aortic dissection compared to controls (31 ) . Our observation of increased amounts of fibulin-1 in nonatherosclerotic tissue from diabetic patients adds to previous findings of arterial ECM accumulation in diabetes (5) (6) (7) (8) . Furthermore, our finding of alterations in arterial fibulin-1 concentrations in relation to elastic fibers in diabetes may relate to findings from other studies showing signs of elastolysis and reduced intimal elastin content in diabetic arteries (14 -16 ) . A potential involvement of elastic fiber alteration in diabetic arteriopathy was underscored by our observation that transcripts for elastin and other elastin-related molecules were increased in diabetic arteries, including fibulin-2 (25 ), as well as MMP-2, a protease capable of degrading elastin (32 ) and previously found to be upregulated in diabetes (11, 12 ) . Interestingly, fibulin-2 has previously been found to be related to diabetic nephropathy (33 ) . Our discovery of increased plasma fibulin-1 concentrations among patients with T2DM complements the findings of augmented fibulin-1 in the arterial wall. Fibulin-1 is one of a few ECM proteins normally found in blood in high concentrations (22 ) , but the origin and clinical significance of fibulin-1 in the blood is not known. We observed increased plasma fibulin-1 concentrations in T2DM patients with prevalent CVD destined for vascular surgery. In the present line of investigations, we did not have the opportunity to include a sex-and age-matched, nondiabetic, non-CVD diseased group. However, with increased plasma fibulin-1 concentrations in the T2DM group, we observed, in a population of T2DM individuals without known or suspected CVD, that plasma concentrations of fibulin-1 were related to Hb A 1c and fasting plasma glucose independent of age. Plasma concentrations of fibulin-1 were increased in patients with signs of initial kidney disease; however, the correlations to metabolic and vascular parameters were also observed in patients having no signs of kidney dysfunction. The 90-kDa size of the fibulin-1 monomer makes it unlikely that kidney filtration plays a major role in regulation of its plasma concentrations, but nothing is known about clearance of this molecule.
In addition to associations to glycemic status, we also observed correlations between plasma fibulin-1 and systolic, as well as diastolic, blood pressure. Moreover, the plasma concentrations correlated modestly with markers of arterial stiffness, i.e., the carotid compliance and pulse pressure, both when calculated directly from brachial pressure measures and when normalized for variability in stroke volume by SVi/PP. Both local and systemic arterial stiffness are known to be affected in diabetes and have been shown to predict cardiovascular events (34 -36 ) . We also found associations between plasma fibulin-1 concentrations and signs of myocardial dysfunction, when judged in relation to left atrial volume index and plasma concentrations of NT-proBNP. The most likely cause of variation in left atrium volume in this study is pressure overload caused by abnormal left ventricular relaxation, known to be present in our diabetic population (23 ) . This overload may at least partly be caused by increased arterial stiffness, which leads to premature return of reflected pulse waves in late systole (34, 37, 38 ) . Taken together, our observations of accumulation of fibulin-1 in relation to arterial elastic fibers in T2DM as well as our plasma findings are compatible with the concept that upregulation of fibulin-1 in diabetes may represent a cross point between metabolically related alterations and increased arterial stiffness (3, 4, 36, 39, 40 ) . A potential limitation of our findings is that both blood pressure and lipid concentrations were decreased in the diabetes groups because of intensive treatment of these modalities. In this regard, it is important to note that we did not find relationships between lipid concentrations and plasma fibulin-1 concentrations or negative correlations to blood pressure. Moreover, we did not find indications that medications for diabetes or CVD were associated with increased fibulin-1 concentrations. On the contrary, the observed positive correlations between fibulin-1 concentrations and Hb A 1c and blood pressure are compatible with the idea that high fibulin-1 reflects hyperglycemia and arterial stiffness. Whether changes in fibulin-1 concentrations might have a causative role in these disorders awaits further analysis, e.g., in transgenic animal models.
Finally, in accordance with the observed association between fibulin-1 and cardiovascular complications, we were able to demonstrate that increased plasma fibulin-1 concentrations are predictive of overall and cardiovascular mortality in T2DM. The association with overall mortality was independent of CVD risk factors (age, sex, cholesterol, previous MI, Hb A 1c , systolic blood pressure, and smoking status), whereas the association with cardiovascular mortality had only borderline significance after adjustments, probably because of limited numbers of participants and because of the association of fibulin-1 with blood pressure. Furthermore, it is difficult to assess cause of death and to evaluate the contribution of CVD in the individual cases because information on death certificates is often limited, and necropsy reports are usually not available. The magnitude of the fibulin-1 HRs were of the same size as the performance of HRs of 2 well-known risk factors, cholesterol and blood pressure, in our study population. Although fibulin-1 was a predictor of mortality independent of several risk factors (age, sex, cholesterol, previous MI, Hb A 1c , systolic blood pressure, and smoking status), future studies will have to be performed to assess whether fibulin-1 is superior to other biomarkers of CVD risk in diabetes.
In conclusion, we have used transcriptomic profiling of well-defined tissue specimens and found fibulin-1 to be upregulated in nonatherosclerotic arterial tissue from T2DM patients compared to control individuals. We also observed increased circulating amounts of fibulin-1 in diabetics and defined the correlations between plasma fibulin-1 and glycemic status, cardiovascular variables, and mortality. Changes in fibulin-1 concentrations were not associated with changes in well-known atherosclerosis markers, i.e., lipid and inflammatory molecules, but appeared to reflect generalized alterations in arterial ECM in diabetes. The occurrence of a biomarker with these characteristics, which is predictive of mortality, is novel and compatible with the hypothesis that in diabetes alterations in arterial ECM play a role in the development of CVD. Although fibulin-1 seems most pertinent to T2DM, it would also be of interest to explore the extent to which it may serve as a biomarker of ECM disruption in nondiabetic individuals.
